Pneumococcal conjugate vaccine is effective in pediatric HSC transplant recipients
This article has no abstract so we have provided the first paragraph of the full text.
Life-threatening pneumococcal infections are common in children who undergo allogeneic hematopoietic stem-cell transplantation (alloHSCT). Vaccination with 23-valent pneumococcal polysaccharide vaccines has been shown to elicit only low response rates as a result of immunologic immaturity of the recipients. A study by Meisel et al. has shown that a heptavalent pneumococcal conjugate vaccine (7vPCV) induced protective antibody responses in children who received an alloHSCT transplant from a related or unrelated donor.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.